Depression is so common now-a-days, given the stress in
fast-tracked life. Nuclear families,
pressure to work & earn for living, travel, stress of job appraisal, career
growth and effects of maternity break on career have caused immense stress in a
Woman’s mid-year life.
It is the support from Parents and Siblings which seems
to be the protective factor to avoid the stress going overboard for many
decades for the birthing woman. Not to mention, the in-laws in most (not all)
Asian families where the support mostly is minimal to a woman during pregnancy
and postpartum. Given the rituals during pregnancy and post-delivery in Asian
families, the clash between the families could damage the morale of the woman,
who loses the love and affection of husband and parents at the same time,
caught between the sleeplessness and the duties of a new mom. However, the term
depression does not go well with men partly, as they might feel guilty for
having been a part of that diagnosis in their wives!
As doctors, we could face a patient on antidepressants
trying to become pregnant or a pregnant woman presenting in low mood. I had a
general discussion with colleagues about which antidepressant is safe in
pregnancy and breastfeeding.
If a woman on antidepressant intends to become pregnant, the
best thing is to provide the information about safety of the medications. If on
paroxetine, it needs to be changed. However, if she is stable for a while on a
safe SSRI or TCA, it is best to continue the same. The question arises,
which is safe, if we were to start one in a woman who is depressed after
becoming pregnant or in postpartum.
Pregnancy:
TCA s and some SSRIs are safe in pregnancy. Tricyclic
antidepressants, such as amitriptyline and imipramine, have lower known risks
in pregnancy than other antidepressants. The risk of adverse
events during pregnancy, in case of overdose is higher than with SSRIs. Hence
SSRIs are preferred during pregnancy in women who are at risk of overdose.
Fluoxetine is the best-documented selective serotonin
re-uptake inhibitor (SSRI) used in pregnancy.
Information on the safety of other SSRIs in pregnancy is
limited. The use of fluoxetine in the first trimester of pregnancy is not
associated with teratogenicity effects. There is small risk of neonatal
withdrawal syndrome characterised by convulsions, irritability and feeding
problems when used in last trimester. We also need to inform patients that
there is a small risk of cardiac defects in babies,
born to mothers on
other SSRIs. Use of SSRIs may be associated with Persistent Pulmonary
hypertension in the new-born and hence, paediatric assessment after delivery is
advised. However, this is not a common side-effect that needs to scare a woman
to deny a worthy medication that could improve her quality of life. The
benefits obviously should outweigh the risks during prescription.
Breast feeding:
The selective serotonin reuptake inhibitors (SSRIs)
sertraline can safely be given to a woman who is
breastfeeding provided the infant is healthy and baby's
progress is monitored. Citalopram and fluoxetine are less preferred as they are
secreted more in breast milk than sertraline; but these could be considered if the woman has been
successfully treated with one of these drugs during pregnancy.
So, Summarising, Fluoxetine is preferred during pregnancy
and sertraline during breastfeeding.
It is better to use the lowest possible (maintenance) dose
and monitor effects (adverse) carefully.
All the more, the
clinical care does not end with prescribing medications. It is best to ensure
that the family around helps the woman to combat the mood and stress. It is the moral,
psycho-social support network that really helps to overcome the stressful
period of pregnancy and delivery.
Reference for MRCOG exams about Depression in Pregnancy and
Breastfeeding:
1. Moses-Kolko EL
et al. Neonatal signs after late in utero exposure to serotonin reuptake
inhibitors: literature review and implications for clinical applications. JAMA
2005;293:2372-83.
2. NICE (February
2007). Antenatal and postnatal mental health.
3. Chambers CD et
al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary
hypertension of the newborn. N Engl J Med. 2006 Feb 9;354(6):579-87
No comments:
Post a Comment